



Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

November 8, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 8, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will report financial results for the quarter ended September 30, 2021 on Monday, November 15, 2021. That same day, Mirum will host a conference call and audio webcast at 1:30 p.m. PT/4:30 p.m. ET to provide a business update.

Conference Call Details:

U.S. toll-free: 844.200.6205
International: 646.904.5544
Passcode: 588077

You may also access the call via webcast by visiting the [Investors & Media](#) section on Mirum's corporate website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum's approved medication is LIVMARLI™ (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the [MARCH](#) Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the [EMBARK](#) Phase 2b study for patients with biliary atresia. In addition, Mirum has an [expanded access program](#) open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Mirum's second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in two registrational studies including the [OHANA](#) Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy and the [VISTAS](#) Phase 2b study for adults with primary sclerosing cholangitis. Mirum is planning to launch a Phase 2b study in primary biliary cholangitis later this year.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.

Follow Mirum on [Twitter](#), [Facebook](#), [LinkedIn](#) and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211108006017/en/): <https://www.businesswire.com/news/home/20211108006017/en/>

Investors:

Ian Clements, Ph.D.
ir@mirumpharma.com

Sam Martin
Argot Partners
ir@mirumpharma.com
212.600.1902

Media:

Erin Murphy
media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.